Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Rhea-AI Summary

Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis, has announced its participation in the upcoming Virtual Investor Summit on August 20th, 2024. The company, which utilizes biomarkers and proprietary augmented intelligence algorithms to assist physicians in locating chronic low back pain sources, will be presenting at 4:00 PM ET.

Investors interested in attending the presentation can access it via the provided webcast link. Additionally, there's an opportunity for one-on-one meetings with Aclarion's management team, which can be arranged through the Investor Summit Group's registration process.

BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20^th, 2024. Investors may request a one-on-one meeting with management by registering here: https://investorsummitgroup.com.

Event: Q3 Investor Summit
Date: August 20, 2024
Presentation Time: 4:00 PM ET
Location: https://www.webcaster4.com/Webcast/Page/3062/51121

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com. 

Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com

FAQ

When is Aclarion (ACON) presenting at the Virtual Investor Summit?

Aclarion (ACON) is presenting at the Virtual Investor Summit on August 20th, 2024, at 4:00 PM ET.

What is the focus of Aclarion's technology?

Aclarion's technology focuses on helping physicians identify the location of chronic low back pain using biomarkers and proprietary augmented intelligence algorithms.

How can investors attend Aclarion's presentation at the Virtual Investor Summit?

Investors can attend Aclarion's presentation via the webcast link: https://www.webcaster4.com/Webcast/Page/3062/51121

Is it possible to schedule a one-on-one meeting with Aclarion's management?

Yes, investors can request a one-on-one meeting with Aclarion's management by registering through the Investor Summit Group's website.

What is Aclarion's stock symbol?

Aclarion's stock symbol is ACON, traded on the Nasdaq.